OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 9, 2020 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Michael Chang, Ph.D. Chairman and CEO, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2019 at 4:30 p.m. PST/ 7:30 p.m EST, in San Francisco, CA. About OBI Pharma, Inc. OBI Pharma has a diverse portfolio of innovative cancer therapies […]

HOMEWhat’s NewNewsOBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2019.Dec.26

OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

2020.Jan.21

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999